Exploring miRNA based approaches in cancer diagnostics and therapeutics

https://doi.org/10.1016/j.critrevonc.2015.10.003Get rights and content

Highlights

  • Biogenesis of miRNA.

  • Role of miRNA in carcinogenesis.

  • miRNA in cancer diagnostics.

  • miRNA in cancer therapeutics.

  • Recent patents on miRNA in cancer.

Abstract

MicroRNAs (miRNAs), a highly conserved class of tissue specific, small non-protein coding RNAs maintain cell homeostasis by negative gene regulation. Proper controlling of miRNA expression is required for a balanced physiological environment, as these small molecules influence almost every genetic pathway from cell cycle checkpoint, cell proliferation to apoptosis, with a wide range of target genes. Deregulation in miRNAs expression correlates with various cancers by acting as tumor suppressors and oncogenes. Although promising therapies exist to control tumor development and progression, there is a lack of efficient diagnostic and therapeutic approaches for delineating various types of cancer. The molecularly different tumors can be differentiated by specific miRNA profiling as their phenotypic signatures, which can hence be exploited to surmount the diagnostic and therapeutic challenges. Present review discusses the involvement of miRNAs in oncogenesis with the analysis of patented research available on miRNAs.

Introduction

Uncontrolled proliferation of damaged cells, as a result of deregulation of genes involved in the cell cycle machinery and apoptosis, leads to tumor formation (Vecchione and Croce, 2010). Accounting for approximately 3% of the human genome, miRNAs are 22 nucleotides long, single stranded RNAs found in both plants and animals (Setoyama et al., 2011). The biogenesis of miRNAs is well defined in literature. Briefly, a stem-loop structure of pri-miRNA (primary miRNA) of about 1 Kb in size, transcribed by RNA polymerase II undergoes a two step maturation phase. Initially, the RNase III enzyme Drosha and ds-RNA binding endonuclease Pasha (DGCR8) process it into a 70 nucleotides pre-miRNA by cleaving both the strands and generating a stem loop structure (Krishnan et al., 2011, Zhiguo et al., 2008). The pre-miRNA is then transported to the cytoplasm with the help of a RAN GTP-dependent transporter exportin 5 for further processing by RNA III enzyme Dicer and ds-RNA binding protein TRBP (Transactivating Response RNA-Binding Protein), hence generating a 22 nucleotides miRNA: miRNA* duplex. The duplex is incorporated to the RISC (RNA induced silencing complex) complex wherein the mature miRNA strand is retained and the miRNA* fragment is degraded, guiding the RISC to the target mRNA molecule for gene regulation, which is a sequence complementarity dependent process. Perfect complementarity of the “seed region” with target mRNA results into its RISC associated degradation while imperfect matching leads to translation repression as 5′ end of miRNA binds to the 3′ UTR (untranslated region) of the target gene (Zhang et al., 2007, Xiangyang et al., 2008, Stefanie et al., 2008) [Fig. 1].

Miss-expression or mutation of factors involved in miRNA biogenesis could result into alterations in miRNA processing, stability, and targeting, hence causing serious ailments including cancers. The potential role of miRNAs in cancer is suggested owing to their involvement in the regulation of cell proliferation and apoptosis by controlling the expression of tumor suppressor genes and oncogenes. Additionally supporting this, about 50% of miRNAs are found to be located at “fragile sites” in the genome, which are the sites mostly amplified or deleted in cancer. Microarray, bead-based flow cytometry, sequencing and RT-PCR (Real Time-polymerase chain reaction) are some of the techniques used for analyzing the differential expression of genes in normal and cancerous cells, to elucidate the exact role of miRNAs in carcinogenesis (Monya, 2010). It has been reported that miR-10b, miR-125b and miR-145 are down-regulated while miR-21 and miR-155 are up-regulated in cancer development, hence playing roles as tumor suppressors and oncogenes, respectively (Thalia et al., 2011). Moreover, rearrangements in the gene regions containing miRNAs have been identified indicating their altered expression levels in the neoplastic cells. Their differential expression profiling thus gives information both on the differentiation state and developmental lineage of tumor, thereby paving way for cancer diagnosis and therapy (Niamh et al., 2009).

Section snippets

Role of miRNAs in cancer development

Studies suggest that miRNAs are majorly involved in the onset and progression of cancer. In lung cancer, the expression of dicer is found to be down-regulated, further decreasing the post-operative survival rate as a result of truncated miRNA maturation process (Ruan et al., 2009). Knock down studies with DICER, DGCR8 and TRBP2 genes shows enhanced tumor formation while re-introduction of these genes cause reduction in tumor growth. Genes from other pathways such as LIN28A block processing of

miRNAs in cancer diagnostics

Cancer, a major cause of mortality worldwide, requires better techniques and treatments for which miRNAs may prove to be incredibly beneficial. Many cancer biomarkers are available for diagnostics; however, they fail to delineate benign and malignant tumors and other benign diseases such as cirrhosis, inflammatory bowel disorder, due to their elevation in these ailments. Some of the commonly used markers are CEA (carcinoembryonic antigen) for colon cancer, AFP (alpha-fetoprotein), an associated

miRNA delivery systems in cancer therapeutics

Owing to the function of miRNAs to be used as tumor suppressors and oncomers, they have a great potential to target the pathways involved in cancer development and metastasis. In cancer therapeutics, miRNAs can be used for degrading the anti-apoptotic genes or can be silenced to up-regulate the tumor suppressor genes. For example the restoration of miR-34 inhibited tumor formation while antagonizing miR-21 using anti-sense oligonucleotides causes pro-apoptotic response. The anti-sense

Circulating miRNAs in therapeutics

Through facilitation of cell–cell communication, circulating miRNAs are suggested to serve as potential therapeutic tools. Based upon over-expression or knocking down of these small molecules, several progressive researches are currently going on for employing them in cancer therapeutics (Zhang et al., 2013). The treatment of colorectal cancer by targeting miR-135b which is abnormally up-regulated in diseased state, causing evasion of apoptosis by down-regulating TGFβR2 (Transforming Growth

Recent patented research on miRNAs

Oncomirs, emerging as novel biomarkers for diagnosis, prognosis and treatment of cancer by employing molecular biology techniques are being extensively patented worldwide, which corresponds to a great research being done in this field. The patenting era for miRNAs began in early 2000s and achieved a peak after 2008, showing the intense research being conducted in this field. Amongst the United States (US), Europe (EP) and WIPO patents, US leads in the number of patented applications followed by

Future prospectives in cancer therapeutics

Cancer being a very complex and multi-factorial disease leaves us with many unexplored questions. Curing cancer to its root requires intensive treatment, but still complications develop owing to the side effects of the therapy due to deficient interruption of multi-signaling oncogenic pathways and drug-induced adverse effects. Therefore, new treatment strategies are required to be developed to improve the clinical outcome and quality of life of patients. Employment of miRNAs for targeting the

Conclusions

miRNAs, an emerging class of gene regulators, are involved in many physiological and pathological processes, including cancer. The characterization of deregulated miRNAs in cellular transformation, benign and malignant states, progression of cancer and as a regulator of multiple biological pathways has immense implications and represents a powerful therapeutic strategy in cancer.

Conflict of interest

Authors declare that they have no conflict of interest.

Acknowledgements

This work was supported by a research grant awarded to Dr. Vibha Rani by the Department of Biotechnology (DBT), Government of India (BT/PR3642/AGR/36/709/2011). We acknowledge Department of Biotechnology, Government of India and Jaypee Institute of Information Technology, deemed to be University for providing the funds and infrastructural support.

References (89)

  • K. Ruan et al.

    MicroRNAs novel regulators in the hallmarks of human cancer

    Cancer Lett.

    (2009)
  • J. Shen et al.

    Plasma microRNAs as potential biomarkers for non-small-cell lung cancer

    Lab. Invest.

    (2011)
  • Y. Zhang et al.

    Progress in microRNA delivery

    J. Control Release

    (2013)
  • Andreas, G.B., Mike, B., Charles, D.J., et al., 2009. miR-34 Regulated Genes and Pathways as Targets for Therapeutic...
  • Andreas, G.B., Mike, B., Charles, D.J., David, B., 2009. mir-21 regulated genes and pathways as targets for therapeutic...
  • R.I. Aqeilan et al.

    miR-15a and miR-16-1 in cancer: discovery, function and future perspectives

    Cell Death Differ.

    (2010)
  • Asuragen, Inc., 2010. Compositions and methods related to mir-16 and therapy of prostate cancer. WO...
  • Asuragen, Inc., 2009. mir-15, mir-26, mir-31, mir-145, mir-147,mir-188, mir-215, mir-216, mir-331, mmu-mir-292-3P...
  • D. Ben-Shushan et al.

    Overcoming obstacles in microRNA delivery towards improved cancer therapy

    Drug Delivery Transl. Res.

    (2014)
  • B. Boyerinas et al.

    The role of let-7 in cell differentiation and cancer

    Endocr. Relat. Cancer

    (2010)
  • California Institute of Technology, 2012. Treatment of autoimmune inflammation using miR-155....
  • R.G. Carrie et al.

    Critical analysis of the potential for microRNA biomarkers in breast cancer management

    Breast Cancer (Dove Med. Press)

    (2015)
  • Charite-Universitatsmedizin Berlin, Technische Universitat Berlin, 2013. MicroRNA target site for cell- or...
  • Y. Chen et al.

    MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G

    Cancer Lett.

    (2008)
  • B. Cherie et al.

    miRNAs in cancer: approaches, aetiology, diagnostics and therapy

    Hum. Mol. Genet.

    (2007)
  • Y.C. Chieh et al.

    miR-34 cooperates with p53 in suppression of prostate cancer by joint regulation of stem cell compartment

    Cell Rep.

    (2014)
  • Children’s Medical Center Corp., Dana-Farber Cancer Institute, Inc., 2012. Lin28-mediated control of let-7 biogenesis....
  • S.S. Chung et al.

    The role of microRNAs in hematopoietic stem cell and leukemic stem cell function

    Ther. Adv. Hematol.

    (2011)
  • Cold Spring Harbor Laboratory, University of North California, 2014. Composition and methods for cancer diagnosis...
  • Council of Scientific and Industrial Research, 2015. Biomarkers useful for detection of types, grades and stages of...
  • M.F.K. Czyzyk et al.

    MiR-155 at the heart of oncogenic pathways

    Oncogene

    (2014)
  • M. Dharanija et al.

    Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures

    Front. Genet.

    (2013)
  • O.D. Elizabeth et al.

    MicroRNAs and their target gene networks in breast cancer

    Breast Cancer Res.

    (2010)
  • Febit Holding GmbH, 2012. miRNA in the diagnosis of ovarian cancer. EP...
  • S. Flavie et al.

    Targeting miR-21 for the therapy of pancreatic cancer

    Mol. Ther.

    (2013)
  • T. Fujiwara et al.

    MicroRNAs in soft tissue sarcomas: overview of the accumulating evidence and importance as novel biomarkers

    Biomed. Res. Int.

    (2014)
  • C.S. Fuziwara et al.

    MicroRNA deregulation in anaplastic thyroid cancer biology

    Int. J. Endocrinol.

    (2014)
  • J.N. Goh et al.

    microRNAs in breast cancer: regulatory roles governing the hallmarks of cancer

    Biol. Rev.

    (2015)
  • K. Goljanek-Whysall et al.

    Regulation of multiple target genes by miR-1 and miR-206 is pivotal for C2C12 myoblast differentiation

    J. Cell Sci.

    (2012)
  • A.J. Granados López et al.

    Multistep model of cervical cancer: participation of miRNAs and coding genes

    Int. J. Mol. Sci.

    (2014)
  • T. Halkova et al.

    MicroRNAs in pancreatic cancer: involvement in carcinogenesis and potential use for diagnosis and prognosis

    Gastroenterol. Res. Pract.

    (2015)
  • H. Hermeking

    The miR-34 family in cancer and apoptosis

    Cell Death Differ.

    (2010)
  • B. Hoffman et al.

    Apoptotic signaling by c-MYC

    Oncogene

    (2008)
  • Hospital Clinic De Barcelona, Centro De Investigacion Biomedica En Red De Enfermedades Hepaticas Y Digestivas, 2013....
  • Hu, Xiaogu, Immune Disease Inst., Lieberman, Judy, et al., 2008. let-7 microRNA and mimetics thereof as therapeutics...
  • M.V. Iorio et al.

    microRNA-205 regulates HER3 in human breast cancer

    Cancer Res.

    (2009)
  • A. Italiano et al.

    The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification

    Genes Chromosomes Cancer

    (2012)
  • M. Jakopovic et al.

    Targeting the epigenome in lung cancer: expanding approaches to epigenetic therapy

    Front. Oncol.

    (2013)
  • S. Krishnan et al.

    Micro RNAs tiny sequences with enormous potential

    Biochem. Biophys. Res. Commun.

    (2011)
  • W. Kwanhian et al.

    MicroRNA-142 is mutated in about 20% of diffuse large B-cell lymphoma

    Cancer Med.

    (2012)
  • Y.C. Liao et al.

    The antileukemia activity of natural product HQ17(3) is possibly associated with downregulation of miR-17-92 cluster

    Biomed. Res. Int.

    (2014)
  • C.G. Liu et al.

    MicroRNA expression profiling using microarrays

    Nat. Protoc.

    (2008)
  • A. Markou et al.

    Prognostic significance of metastasis-related microRNAs in early breast cancer patients with a long follow-up

    Clin. Chem.

    (2014)
  • P.P. Medina et al.

    OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma

    Nature

    (2010)
  • Cited by (357)

    View all citing articles on Scopus
    View full text